Transaction Tuesday

Forget merger Monday, it's all about Transaction Tuesday. Indeed, there were four major deals announced in London this morning - they were:

1. Zurich considering a £5 billion plus takeover bid for RSA.

Hikma Pharmaceuticals eyes $1 billion purchase of CorePharma

I realise most of the dealmaking community is currently focused on the risk that some large pharmaceutical deals may collapse. But I have stumbled across a potential pharmaceutical deal that is unlikely to be affected by the US government's attempt to clamp down on corporate "tax inversions".

I have been told by reliable sources that FTSE 250-listed Hikma Pharmaceuticals, which manufactures branded and non-branded generic pharmaceutical products, has been looking at buying US-based CorePharma for up to $1 billion.

Another day, another multibillion dollar pharma deal - part 2

Is Hikma Pharmaceuticals the next takeover target in the pharmaceutical sector?

The boys over The Motley Fool certainly seem to think so.